Chemoimmunomodulation of MDSCs as a novel strategy for cancer therapy

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Myeloid-derived suppressor cells (MDSCs) are key regulators of the tumor immune microenvironment and represent a significant obstacle to effective cancer immunotherapy.
• MDSCs, particularly the M2 subtype, promote tumor progression and immune evasion.

Purpose of the Study:

• To investigate the potential of Docetaxel and Icariin in targeting and modulating MDSCs for enhanced cancer immunotherapy.
• To determine the effects of these agents on MDSC subsets and their subsequent impact on anti-tumor immune responses.

Main Methods:

• In vitro and in vivo studies were conducted to assess the effects of Docetaxel and Icariin on MDSCs.
• Flow cytometry and immunological assays were used to analyze MDSC apoptosis, polarization, and T cell function.
• Tumor growth was monitored in vivo following treatment.

Main Results:

• Docetaxel and Icariin demonstrated preferential induction of apoptosis in M2-MDSCs.
• Treatment led to the polarization of surviving MDSCs towards an M1-like phenotype.
• Restoration of T cell function was observed, correlating with significant tumor growth retardation in vivo.

Conclusions:

• Docetaxel and Icariin represent a promising therapeutic strategy for overcoming MDSC-mediated immunosuppression in cancer.
• Targeting MDSC apoptosis and polarization can restore anti-tumor immunity and inhibit tumor progression.
• This combination therapy holds potential for improving the efficacy of cancer immunotherapy.